1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Shanxi Zhendong Pharmaceutical Co.,Ltd

Shanxi Zhendong Pharmaceutical Co.,Ltd

300158.SZ
Shanxi Zhendong Pharmaceutical Co.,LtdCN flagShenzhen Stock Exchange
4.90
CNY
+0.16
- -
4.86BMarket Cap
Shanxi Zhendong Pharmaceutical Co.,Ltd
300158.SZ
(Shenzhen Stock Exchange)

Recent

price

4.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
1.26
2.15
2.25
2.43
2.88
3.33
3.93
4.49
7.22
3.3
4.28
4.72
4.96
3.63
3.53
2.9
3.03
Revenue per Share
0.16
0.21
0.21
0.16
0.13
0.07
0.11
0.28
0.58
-0.14
0.14
0.26
2.55
-0.05
-0.04
-1.3
-1.4
Basic EPS, GAAP
0.03
-0.11
-0.76
-0.28
-0.54
-0.12
0.18
-0.26
-0.01
0.13
0.16
0.04
0.13
-0.06
-0.36
-0.44
-0.23
Free Cash Flow per Basic Share
0.02
0.02
0.09
0.1
0.06
0.09
0.15
0.27
0.1
0.05
0.02
0.08
0.19
2.71
- -
- -
- -
Dividend per Share
0.47
0.73
0.64
0.94
1.04
1.06
1.11
1.22
2.22
1.38
1.53
1.72
3.73
0.98
0.94
-0.37
-0.39
Book Value per Share
0.63
3.89
2.66
2.56
2.56
2.56
2.61
3.27
5.16
2.47
2.62
2.85
7.37
4.6
4.52
3.2
3.33
Tangible Book Value per Share
419
433
570
572
576
576
576
731
517
1,035
1,028
1,028
1,027
1,028
1,028
1,024
964
Basic Weighted Avg Shares
529
930
1,281
1,387
1,658
1,919
2,262
3,283
3,732
3,420
4,399
4,848
5,094
3,729
3,626
2,971
2,921
Sales/Revenue/Turnover
18.16
12.99
9.48
7.07
6.94
3.16
4.89
8.27
12.19
3.09
5.97
7.33
4.13
-2.75
-1.82
-11.4
-11.25
Operating Margin (%)
18
20
18
36
43
74
82
114
110
114
116
166
125
126
122
115
- -
Depreciation Expense
68
92
120
91
74
42
65
203
302
-147
143
262
2,617
-51
-44
-1,329
-1,351
Net Income, GAAP
17.81
15.86
13.06
19.66
28.6
29.49
19.77
17.18
19.34
- -
28.41
21.46
16.25
- -
- -
- -
169.46
Effective Tax Rate (%)
12.87
9.9
9.35
6.6
4.46
2.19
2.86
6.19
8.08
-4.31
3.25
5.41
51.38
-1.38
-1.21
-44.72
-46.25
Profit Margin (%)
51
1,441
1,095
673
569
524
-127
1,478
1,721
1,696
1,866
2,111
6,623
3,674
3,543
1,961
1,841
Working Capital
- -
6
11
14
20
24
60
39
200
292
284
20
101
1
2
1
1
LT Debt
359
1,781
1,858
1,900
1,958
1,970
2,030
5,272
5,558
5,300
5,441
5,625
8,054
5,223
5,144
3,660
3,617
Total Equity
17.18
8.09
5.31
3.82
3.7
1.86
3.57
5.43
6.21
- -
3.26
4.87
2.44
- -
- -
- -
- -
Return on Invested Capital (%)
26.16
20.08
22.44
14.47
9.78
7.01
6.84
16.62
20.48
- -
8.26
13.97
83.64
- -
- -
- -
-874.33
Return on Capital (%)
42.1
36.04
35.32
20.25
13
6.95
10.37
26.48
29.5
-11.42
9.51
15.7
93.39
-2.12
-4.44
- -
-0.3
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
40
16
2
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,005
1,005
1,005
Market Capitalization
4,435
3,848
4,243

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
3,216
2,858
2,683
Cash, Cash Equivalents & STI
1,574
1,174
1,030
Accounts Receivable, Net
520
667
733
Inventories
776
643
637
Total Current Liabilities
1,255
945
842
Payables & Accruals
- -
- -
- -
ST Debt
40
16
2
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.72%
-3.79%
-28.85%
Free Cash Flow
-472%
112.86%
22.69%
Net Income, GAAP
375.78%
757.36%
2,920.55%
Sales/Revenue/Turnover
6.46%
-6.47%
-18.06%
Total Cash Common Dividend
170.16%
328.76%
-52.26%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
951
981
851
842
3,626
2024
782
724
763
702
2,971
2025
755
702
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.04
2024
0.02
- -
- -
- -
-1.3
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Cellular Goods PLC (CBX.L)
Probi AB (publ) (0GZB.L)
Ligand Pharmaceuticals, Inc. (LGNXZ)
Alar Pharmaceuticals Inc. (6785.TWO)
Spencer Pharmaceutical Inc. (SPPH)
Tsuruha Holdings Inc. (3391.T)
Business
Shanxi Zhendong Pharmaceutical Co.,Ltd, alongside its affiliated entities, focuses on the research, development, production, and commercialization of a wide array of pharmaceutical products and traditional Chinese medicines across China. The company develops both innovative and generic medications, addressing therapeutic areas such as oncology, cardiovascular health, dermatological conditions, digestive disorders, urology, and infectious diseases. Beyond conventional pharmaceuticals and Chinese herbal formulations, Shanxi Zhendong has broadened its portfolio to include active pharmaceutical ingredients, functional foods, and home care items. The firm actively manages a complete traditional Chinese medicine supply chain, encompassing everything from cultivation to processing. Recent activities include advancing Phase IIa clinical trials for its Class 1.1 traditional Chinese medicine, Xinglou Chengqi Granules, designed to address phlegm and promote bowel movements, with initial patient enrollment occurring in November 2025. The company's product offerings are delivered in diverse formats. Shanxi Zhendong Pharmaceutical Co.,Ltd maintains its primary operations in Changzhi, China.